FierceBiotech Feb 18, 2026 Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal
FierceBiotech Feb 18, 2026 Sensei steps back from brink by finding Faeth and its phase 2-stage cancer drug
FierceBiotech Feb 18, 2026 Gut-focused Rasayana ingests gastrointestinal candidate in $36M licensing deal
FierceBiotech Feb 18, 2026 Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study
FierceBiotech Feb 18, 2026 Korsana crosses into crowded Alzheimer's field with $175M and anti-amyloid antibody
FierceBiotech Feb 18, 2026 Immunology CRO RoukenBio pens pact with AVS Bio for more predictable antibody development
FierceBiotech Feb 17, 2026 Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering
FierceBiotech Feb 17, 2026 Sanofi points to 'key opportunity' for Teva-partnered IBD in long-term data
FierceBiotech Feb 17, 2026 Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push
FierceBiotech Feb 17, 2026 Novocure gets FDA nod for tumor-treating electric fields targeting pancreatic cancer
FierceBiotech Feb 17, 2026 Gilead’s latest synthetic lethal therapy comes via $1.5B deal with China’s Genhouse
FierceBiotech Feb 16, 2026 Biopharma funding to experience 'continued, albeit disciplined' recovery in 2026: PitchBook
FierceBiotech Feb 14, 2026 'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments
FierceBiotech Feb 13, 2026 With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment